Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
1H2026First half of 2026
1H2027First half of 2027
1Q2026First quarter of 2026
1Q2027First quarter of 2027
2Q26Second quarter of 2026
AAAAIAmerican Academy of Allergy, Asthma & Immunology
AAE-C1-INHAcquired angioedema due to C1 inhibitor deficiency
AAE-C1INHAcquired angioedema due to C1 inhibitor deficiency
ACAREAngioedema Centers of Reference and Excellence
ACEAngiotensin-converting enzyme
ADLActivities of daily living
ADRAdverse drug reaction
AEAdverse event
AE-BKBradykinin-mediated angioedema
AE-QoLAngioedema Quality of Life Questionnaire
AHFSAmerican Hospital Formulary Service
AHRQ-HCUPAgency for Healthcare Research and Quality Healthcare Cost and Utilization Project
AMMAutorisation de mise sur le marché (marketing authorization)
AMRAAngioedema Symptom Rating Scale
AMRA-3Three-item Angioedema Symptom Rating Scale
AMRA-5Five-symptom composite Angioedema Symptom Rating Scale
ANGPT1Angiopoietin-1 gene
AOHAngio-œdème héréditaire (hereditary angioedema)
APAsia-Pacific
APIActive pharmaceutical ingredient
ASMRAmélioration du service médical rendu (improvement in medical benefit)
ASPAverage sales price
ATEArterial thromboembolism
AUCArea under the plasma concentration-time curve
AUCinfArea under the plasma concentration-time curve from time zero to infinity
AUClastArea under the plasma concentration-time curve from time zero to the last quantifiable concentration
B2RBradykinin B2 receptor
BCRPBreast cancer resistance protein
BDKRB2Bradykinin receptor B2 gene
BIDTwice daily
Big4Big Four (Department of Veterans Affairs, Department of Defense, Public Health Service, and Coast Guard) price
BKBradykinin
BK-AEBradykinin-mediated angioedema
Bk2RBradykinin B2 receptor
BMIBody mass index
C-QTcFConcentration-QTcF
C0.25hPlasma concentration at 0.25 hours
C1-INHC1 esterase inhibitor
C1-INH-HAEHereditary angioedema due to C1 inhibitor deficiency
C1-INH-SCSubcutaneous C1 esterase inhibitor
C1INHC1 esterase inhibitor
C1INH-HAEHereditary angioedema due to C1 inhibitor deficiency
C4Complement component 4
CDMOContract development manufacturing organization
CFSCascade family screening
CIConfidence interval
CL/FTotal apparent body clearance
CmaxMaximum plasma concentration
COCardiac output
CoAsCaregivers of adult patients
CoPsCaregivers of pediatric patients
CPN1Carboxypeptidase N subunit 1 gene
CPOCommercial Packaging Organization
CtroughTrough plasma concentration
CVCardiovascular
CVADCentral venous access device
CYPCytochrome P450
DBPDiastolic blood pressure
DESDiscrete event simulation
EAEach
EAACIEuropean Academy of Allergy and Clinical Immunology
EAGExternal Assessment Group
EAMSEarly Access to Medicines Scheme
EAPExpanded Access Program
EC50Half-maximal effective concentration
EC85Concentration producing 85% of the maximal effect
ECGElectrocardiogram
EDEmergency department
EEAEuropean Economic Area
eGFREstimated glomerular filtration rate
EMAEuropean Medicines Agency
eMITElectronic market information tool
EoPEnd of Progression
ePROElectronic patient-reported outcome
EQ-5DEuroQol 5-Dimensions
EQ-5D-5LEuroQol 5-Dimensions, 5-level version
EREmergency room
EUEuropean Union
EudraCTEuropean Union Drug Regulating Authorities Clinical Trials Database
EUREuro
F12Coagulation factor XII gene
FAERSFDA Adverse Event Reporting System
FASFull analysis set
FCTFilm-coated tablet
FDAFood and Drug Administration
FFPFresh frozen plasma
FPFrozen plasma
FSSFederal Supply Schedule
FXIICoagulation factor XII
FXIIaActivated coagulation factor XII
G-BAGemeinsamer Bundesausschuss (Federal Joint Committee)
GA‐NRSGeneral Anxiety Numeric Rating Scale
GDPGross domestic product
GLPGood Laboratory Practice
GPCRsG protein-coupled receptors
HAHereditary angioedema
HADSHospital Anxiety and Depression Scale
HAEHereditary angioedema
HAE-1Hereditary angioedema type 1 (C1 inhibitor deficiency)
HAE-1/2Hereditary angioedema type 1 or type 2
HAE-1/2/3Hereditary angioedema type 1, type 2, or type 3
HAE-2Hereditary angioedema type 2 (C1 inhibitor dysfunction)
HAE-ANGPTHereditary angioedema associated with an angiopoietin-1 gene variant
HAE-BOIS-EuropeHereditary Angioedema Burden of Illness Study in Europe
HAE-C1-INHHereditary angioedema due to C1 inhibitor deficiency
HAE-C1INHHereditary angioedema due to C1 inhibitor deficiency
HAE-CPNHereditary angioedema associated with a carboxypeptidase N gene variant
HAE-CPN1Hereditary angioedema associated with a carboxypeptidase N subunit 1 gene variant
HAE-DAB2IPHereditary angioedema associated with a DAB2 interacting protein gene variant
HAE-FXIIHereditary angioedema associated with a factor XII gene variant
HAE-HSSTHereditary angioedema associated with a heparan sulfate-glucosamine 3-O-sulfotransferase 6 gene variant
HAE-KNGHereditary angioedema associated with a kininogen 1 gene variant
HAE-MYOFHereditary angioedema associated with a myoferlin gene variant
HAE-nC1-INHHereditary angioedema with normal C1 inhibitor
HAE-nC1INHHereditary angioedema with normal C1 inhibitor
HAE-nl-C1INHHereditary angioedema with normal C1 inhibitor
HAE-PDHereditary angioedema as the principal diagnosis
HAE-PLGHereditary angioedema associated with a plasminogen gene variant
HAE-UNKHereditary angioedema with normal C1 inhibitor of unknown cause
HAEAHereditary Angioedema Association
HASHaute Autorité de Santé (French National Authority for Health)
HCHFHigh-calorie, high-fat
HCPHealthcare professional
HCPCSHealthcare Common Procedure Coding System
HCRUHealthcare resource utilization
HDI-SFHamilton Depression Inventory-Short Form
hERGHuman ether-à-go-go-related gene
HIVHuman immunodeficiency virus
HKHong Kong
HRHazard ratio; heart rate
HRQoLHealth-related quality of life
HS3ST6Heparan sulfate-glucosamine 3-O-sulfotransferase 6 gene
ICD-9-CMInternational Classification of Diseases, Ninth Revision, Clinical Modification
ICERInstitute for Clinical and Economic Review; incremental cost-effectiveness ratio
ICURIncremental cost-utility ratio
INDInvestigational New Drug
INJInjection
IPInpatient
IQRInterquartile range
IRImmediate release
IRTInteractive response technology
ITCIndirect treatment comparison
IUInternational units
IVIntravenous
KbAntagonist equilibrium dissociation constant
KiInhibition constant
KKSKallikrein-kinin system
KNG1Kininogen 1 gene
LELaryngeal edema
LSLeast squares
LSMLeast squares mean
LTPLong-term prophylaxis
MAMassachusetts
MAAMarketing authorization application
MADMultiple ascending dose
MAPMean arterial pressure
MIDMinimal important difference
mITTModified intention-to-treat
MMRMMixed model for repeated measures
MNARMissing not at random
MSCSMean Symptom Complex Severity
MYOFMyoferlin gene
N/ANot applicable
NANorth America; not available
NDANew drug application
NDCNational Drug Code
NENot estimable
NEDSNationwide Emergency Department Sample
NICENational Institute for Health and Care Excellence
NJNew Jersey
NOAELNo-observed-adverse-effect level
NRSNumeric rating scale
ODOn-demand
ODTOn-demand treatment
OLEOpen-label extension
OMIMOnline Mendelian Inheritance in Man
OP/EDOutpatient or emergency department
OROdds ratio
ORPHAOrphanet
P-gpP-glycoprotein
PDPharmacodynamics
pd-C1INHPlasma-derived C1 inhibitor
pdC-1INHPlasma-derived C1 inhibitor
pdC1-INHPlasma-derived C1 inhibitor
pdC1INHPlasma-derived C1 inhibitor
PDUFAPrescription Drug User Fee Act
PFPreservative-free
PFSPrefilled syringe
PGI-CPatient Global Impression of Change
PGI-SPatient Global Impression of Severity
PIPPaediatric investigation plan
PKPharmacokinetics
PK/PDPharmacokinetic/pharmacodynamic
PKaPlasma kallikrein
PKKPrekallikrein
PLC-CPosttraumatic Stress Disorder Checklist, Civilian Version
PLGPlasminogen gene
PLNPolish złoty
PMPaediatric investigation plan modification
PPPYPer patient per year
PPYPer patient-year
PRFsPatient record forms
PROPatient-reported outcome
PTSDPosttraumatic stress disorder
PVsPrognostic variables
PWDRPowder
QALYQuality-adjusted life-year
QoLQuality of life
QTElectrocardiographic interval from the onset of the QRS complex to the end of the T wave
QTcQT interval corrected for heart rate
QTcFQT interval corrected for heart rate by the Fridericia formula
rC1-INHRecombinant C1 inhibitor
RCTRandomized controlled trial
rhC1-INHRecombinant human C1 inhibitor
rhC1INHRecombinant human C1 inhibitor
RoWRest of world
rrmRepeated-measures correlation coefficient
RWEReal-world evidence
s.c.Subcutaneous
SADSingle ascending dose
SAD-POMSingle ascending dose, proof of mechanism
SAEsSerious adverse events
SBPSystolic blood pressure
SCSubcutaneous
SCMStandard caloric meal
SDStandard deviation
SDPSolvent detergent-treated plasma
SEStandard error
SERPING1Serpin family G member 1 gene (encodes C1 inhibitor)
SF-1212-Item Short Form Health Survey
SF-3636-Item Short Form Health Survey
SMRService médical rendu (medical benefit)
SOCSystem organ class
SOLSolution
t1/2Elimination half-life
TATranexamic acid
TEThromboembolic
TEAETreatment-emergent adverse event
TEMsTreatment effect modifiers
TEQTreatment Effect Questionnaire
TESAEsTreatment-emergent serious adverse events
tmaxTime to maximum plasma concentration
TOSTreatment Outcome Score
TQTThorough QT
TRAETreatment-related adverse event
TSQMTreatment Satisfaction Questionnaire for Medication
TTCRTime to complete resolution
TTOTime trade-off
UKUnited Kingdom
USUnited States
USAUnited States of America
VADepartment of Veterans Affairs
VASVisual analog scale
VAS-3Visual analog scale, 3-symptom composite
VAS-5Visual analog scale, 5-symptom composite
VATValue-added tax
VEGFVascular endothelial growth factor
VILVial
VTEVenous thromboembolism
WACWholesale acquisition cost
WAOWorld Allergy Organization
WHOWorld Health Organization
WPAI-GHWork Productivity and Activity Impairment-General Health questionnaire
XRExtended release